HEC921
/ HEC Pharm
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 26, 2025
A novel Ly6G6D/4-1BB bispecific antibody targeting DNA mismatch repair proficient colorectal cancers shows potent antitumor activities
(AACR 2025)
- "Initial drug feasibility and toxicity studies results of HEC921 were favorable. Overall result demonstrated that HEC921 is a promising candidate for Ly6G6D positive cancer immunotherapy."
IO biomarker • Mismatch repair • pMMR • Colorectal Cancer • Oncology • Solid Tumor • IFNG • IL2 • IL4 • LY6G6D
1 to 1
Of
1
Go to page
1